Arog Pharmaceuticals, Inc.
Privately held: no public share price
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | FLT3 (including D835/ITD mutants), also PDGFR-alpha/betaSmall molecule | Acute Myeloid Leukemia |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
5 November 2025Topline resultCrenolanibPhase 3 of crenolanib plus salvage chemotherapy (NCT03250338) in R/R FLT3-mutated AML met its primary endpoint (EFS)
Arog Pharmaceuticals, Inc. · Source ↗
Financial reports
No financial reports recorded.